NeuroScientific Biopharmaceuticals’ Lead Candidate, EmtinB, Shows Promise in Preclinical Model of MS

NeuroScientific Biopharmaceuticals (NSB)’s lead candidate EmtinB induces significantly greater myelin regeneration in a cellular model of multiple sclerosis (MS) than the market-leading therapy Copaxone, the company announced. “These results represent a potential breakthrough in the treatment of MS as there are currently no approved therapeutic drugs available to patients that…

Obesity Linked to Faster Optic Nerve Atrophy, Study Finds

Multiple sclerosis (MS) patients who are obese experience faster degeneration in optic nerve tissue than do those of normal weight, an observational study found. Since optic nerve degeneration correlates with greater nerve loss in the brain, measuring changes in this tissue may be a feasible way to determine…